SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after reaching a 52-week high ahead of an expected Q3 report, with traders watching BRIUMVI sales and whether results support the rally. Buyout speculation and possible short covering are also prominent, but the acquisition talk is unconfirmed and some traders attribute the strength to the companys operating momentum instead.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and heavy AI infrastructure spending drove debate, as investors weighed weaker-than-expected results and sharply negative free cash flow against accelerating AWS growth and its outlook. Traders were split between concerns that cash burn and rising investment could pressure the stock and dip-buyers who viewed the initial selloff as overdone; shares rebounded substantially from their lows.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results and strength in parks and streaming have renewed optimism, with traders pointing to analyst upgrades and a potential technical breakout. Others remain skeptical, citing Disneys long-running share-price stagnation and resistance levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels steep drop followed weak forward guidance despite a solid quarter, with traders focused on softer PC demand, manufacturing constraints and analyst downgrades; the pressure also fed into a broader semiconductor and tech selloff. The community is split between calling the reaction excessive and buying the dip, and warning that the outlook and execution problems could prolong the decline.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas prices slide amid mild-weather forecasts that point to weaker heating demand, with surplus inventories adding pressure. Traders are split between buying the decline ahead of winter and expecting further weakness if warm conditions persist; colder forecasts or storage data are seen as potential catalysts for a shift.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the November 14 FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer, with traders weighing the Phase 3 results and recent positive biliary-cancer data against regulatory concerns, including the lack of statistically significant overall-survival results. Bulls see approval potential and broader promise for the drug, while skeptics stress that the decision remains uncertain and could hinge on FDA concerns about the trial population or manufacturing.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders focusing on the amended upper-limb-function data and recent rare-disease discussions. New commercial-launch job postings and other FDA approvals have fueled optimism about a favorable decision, while skeptics caution that neither hiring nor regulatory flexibility guarantees approval and debate the risk of a CRL; some also attribute price swings to short covering or rumors of a leak.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL combination drew attention after Phase 2 NEOASIS data at ESMO showed strong pathologic responses in a small dMMR colon cancer cohort, alongside discussion of sarcoma results. Traders called the findings encouraging but debated their significance given the small, early-stage studies and awaited Phase 3 confirmation, while some questioned why the share price weakened despite the data and raised dilution and execution concerns.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,155,828.93500734 in circulation. The last known price of Hedera is 0.07221819 USD and is up 4.74 over the last 24 hours. It is currently trading on 465 active market(s) with $92,347,671.42 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBARs sharp rally and elevated volume are being linked by traders to IBM-related cloud news and Hederas reported connections to NVIDIAs AI safety platform. Enthusiasm over enterprise and AI use cases is tempered by profit-taking and skepticism that the announcements will translate into meaningful adoption or token demand.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report and narrower 2026 production guidance are driving the selloff, with traders focusing on weaker results and production setbacks, including at Cigar Lake. Some see the report as disappointing and the stock as overvalued, while long-term bulls point to firm uranium prices and nuclear demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CHWY Stock Heads For Worst Week Since February: Analyst Downgrades On ‘Little Reason To Outperform Market’

Equity

Evercore ISI downgraded Chewy, citing slowing organic growth and limited catalysts. 


McDonald's Confirms Return Of Fan-Favorite Snack Wrap

The menu item was launched in the U.S. in 2006 and discontinued in 2016.


First Trust Exchange-Traded Fund IV - FT Vest DJIA Dogs 10 Target Income ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Evercore ISI downgraded Chewy to In Line from Outperform and kept its $25 price target.&nbsp;</li><li>Analyst Mark Mahaney cited slowing organic growth and said the stock needs a clear growth catalyst to outperform.</li><li>On Stocktwits, retail sentiment improved to ‘extremely bullish’ territory.&nbsp;</li></ul><p>Chewy Inc. (CHWY) stock is heading toward its worst weekly performance since February as investors digest a cautious analyst downgrade. Evercore ISI cut the pet retailer’s rating despite a raised outlook, citing slowing 5.7% organic growth and limited near-term catalysts for meaningful upside.&nbsp;</p><p>Chewy stock edged nearly 1% lower in Thursday’s premarket and has slumped over 12% so far this week.&nbsp;</p><h2 class="st-heading-2">Evercore Says Chewy’s Growth Losing Momentum</h2><p>Evercore ISI analyst Mark Mahaney downgraded Chewy to ‘In Line’ from ‘Outperform’ and maintained a $25 price target, implying a 20% upside to the stock’s last closing price. The change followed the company's fiscal second-quarter (Q2) results, which the firm characterized as a “very modest beat &amp; raise.”</p><p>Mahaney pointed to a slowdown in Chewy's organic expansion, which has reached 5.7%. He expects the weaker growth trend to persist in both the immediate and intermediate periods, limiting the potential for a stronger stock performance.</p><p>The analyst sees "little reason for the stock to outperform the market from here" unless the company shows a clear new growth driver or meaningful business improvement.&nbsp;</p><h2 class="st-heading-2">Chewy’s Q2 Performance And Outlook&nbsp;</h2><p>Chewy’s Q2 sales&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chwy-stock-hits-over-1-month-low-after-flat-q2-gross-margin-overshadows-raised-outlook/cZt7IpqRJzm">increased</a> 7.3% to $3.33 billion, meeting Wall Street’s consensus estimate as per Fiscal.ai data, while adjusted EBITDA rose 23.7% to $226.7 million. The company raised its FY26 sales outlook to $13.46 billion-$13.57 billion and tightened its EBITDA margin forecast. The company’s gross margin held steady at 30.4%, while adjusted EPS came in at $0.36.</p><p>“We are not assuming a meaningful consumer recovery for the balance of this fiscal year. Instead, our confidence remains grounded in what we can control, gaining share, growing and retaining customers, scaling health and driving structural efficiencies across the business,” said CEO Sumit Singh in the earnings call.&nbsp;</p><h2 class="st-heading-2">CHWY Stock: Retail View&nbsp;</h2><p>On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. The stock saw a whopping 6,100% surge in message volume over the past week with a 0.4% gain in watchers.&nbsp;</p><p>A user&nbsp;<a href="https://stocktwits.com/Benjamin1985/message/663902862">said</a>, “The reality is that consumer behavior has shifted heavily toward online shopping. People can buy products 24/7 from virtually anywhere, and e-commerce is a major part of how business is done today. It’s 2026, not 1950. Online shopping is not some niche concept—it’s a fundamental part of modern retail. I’m assuming all the bears here are&nbsp; 70 and up.”</p><p>CHWY stock has cratered over 37% year-to-date.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-stock-slips-overnight-director-mark-stevens-dumps-640-m-in-stock-amid-ai-testing-capacity-strains/cZtaciXRJCL">Nvidia Stock Slips Overnight: Director Mark Stevens Dumps $640M In Stock Amid AI Testing Capacity Strains</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a smartphone displays the logo of Chewy, Inc.

Evercore ISI downgraded Chewy, citing slowing organic growth and limited catalysts.

Chewy Inc

First Trust Exchange-Traded Fund IV - FT Cboe Vest DJIA Dogs 10 Target Income ETF

Corgi ETF Trust I. - Corgi Lifestyle Brands ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

DOGG First Trust Exchange-Traded Fund IV - FT Cboe Vest DJIA Dogs 10 Target Income ETF

Fundamentals

Latest DOGG News